Thus, targeting thrombin, and consequently PAR1, through dabigatran, a direct thrombin inhibitor, can be proposed as a potential therapeutic strategy to mitigate coagulopathy and inflammatory dysfunctions in COVID-19, offering perspectives on novel therapeutic approaches [248]. The gene discussed is F2R; the disease is COVID-19.